SeaStar Medical Announces The Publication Of A Peer-Reviewed Article In 'Nature Scientific Reports' Describes The Mechanism Of Action Of The Co's Selective Cytopheretic Device In The Immunomodulation Of Excessive Inflammation
SeaStar Medical Announces The Publication Of A Peer-Reviewed Article In 'Nature Scientific Reports' Describes The Mechanism Of Action Of The Co's Selective Cytopheretic Device In The Immunomodulation Of Excessive Inflammation
SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the publication of a peer-reviewed article in Nature Scientific Reports that describes the mechanism of action of the Company's Selective Cytopheretic Device (SCD) in the immunomodulation of excessive inflammation. "Immunomodulatory effects of a cell progressing device to ameliorate dysregulated hyperinflammatory disease states," authored by Angela J. Westover, H. David Humes and Christopher J. Pino, (2024) 14:12747, investigated the SCD as an evolving approach to treating organ dysfunction arising from hyperinflammation and the cytokine storm by processing leukocytes in an extracorporeal circuit.
SeaStar Medical Holding Corporation（納斯達克：ICU）是一家商業化醫療器械公司，開發專有解決方案以減輕高炎症對重要器官的影響，並宣佈在Nature Scientific Reports上發表了一篇同行評審文章，描述了該公司的選擇性細胞網器（SCD）在免疫調節過度炎症中的作用機制。“一種細胞進展裝置的免疫調節作用，以改善失調的高炎症病態，”由安吉拉·J·威斯特、H·戴維·休姆斯和克里斯托弗·J·皮諾（2024）14:12747撰寫，研究了SCD作爲處理體外循環中白細胞的進化方法，以治療因高炎症和細胞因子風暴而引起的器官功能障礙。Nature Scientific Reports“具有細胞進展裝置的免疫調節作用，以改善失調的高炎症病態”的衆合著者安吉拉·J.韋斯特、H·大衛·休姆斯和克里斯托弗·J·皮諾在2024年第14卷第12747頁發表的調查研究中研究了SCD作爲一種處理體外循環中白細胞的進化方法，以治療因高炎症和細胞因子風暴而引起的器官功能障礙。
譯文內容由第三人軟體翻譯。